Back to Search
IAN FLINN, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1417990367IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
41006(TN)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Class of 1990
Research & Publications (20)
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
PMID 17283364·J Clin Oncol·2007
3-trial
Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.
PMID 19544775·Med Phys·2009
3-trial
Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies.
PMID 18390348·IEEE Trans Med Imaging·2008
4-observational
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.
PMID 17889355·Biol Blood Marrow Transplant·2007
2-rct
Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
PMID 18220907·Curr Stem Cell Res Ther·2007
6-review
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
PMID 17671129·Clin Cancer Res·2007
3-trial
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
PMID 17283363·J Clin Oncol·2007
3-trial
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
PMID 17380530·Cancer·2007
3-trial
Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
PMID 17438098·Clin Cancer Res·2007
8-other
Management of symptomatic, untreated chronic lymphocytic leukemia.
PMID 17097783·Blood Rev·2007
6-review
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.
PMID 17979571·Cancer Biother Radiopharm·2007
1-meta
Blood and bone marrow transplantation for patients with Hodgkin's and non-Hodgkin's lymphoma.
PMID 16704172·Cancer Treat Res·2006
6-review
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
PMID 16832816·Cancer·2006
3-trial
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
PMID 16690521·Leuk Lymphoma·2006
8-other
Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
PMID 16920563·Biol Blood Marrow Transplant·2006
4-observational
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
PMID 16507273·J Natl Compr Canc Netw·2006
6-review
A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
PMID 16518606·Ann Hematol·2006
3-trial
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
PMID 16545725·Biol Blood Marrow Transplant·2006
3-trial
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
PMID 15916806·Leuk Res·2005
3-trial
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
PMID 16322303·Clin Cancer Res·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 250 25TH AVE N, SUITE 412
NASHVILLE, TN 37203 - Phone
- (615) 986-7600
Quick Facts
- NPI
- 1417990367
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile